Fordyce Marshall 4

4 · Vera Therapeutics, Inc. · Filed Jan 10, 2025

Form 4

Period: 2025-01-08

DirectorPRESIDENT AND CEO

Transactions

Exercise/Conversion
Class A Common Stock
2025-01-08$2.90/sh+9,975$28,896→ 153,578 total
Sale
Class A Common Stock
2025-01-08$41.53/sh−9,975$414,297→ 143,603 total
Exercise/Conversion
Class A Common Stock
2025-01-08$2.90/sh+5,650$16,367→ 149,253 total
Sale
Class A Common Stock
2025-01-08$42.03/sh−5,650$237,489→ 143,603 total
Exercise/Conversion
Class A Common Stock
2025-01-08$2.90/sh+1,875$5,432→ 145,478 total
Sale
Class A Common Stock
2025-01-08$42.00/sh−1,875$78,750→ 143,603 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-01-08−1,875→ 609,051 total
Exercise: $2.90Exp: 2030-12-15→ Class A Common Stock (1,875 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-01-08−15,625→ 610,926 total
Exercise: $2.90Exp: 2030-12-15→ Class A Common Stock (15,625 underlying)

Holdings

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
[F2]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.85, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
[F3]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.19, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
[F4]1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.

Documents

1 file